Rethinking Scale, Agility, and Innovation in Pharma Agency Partnerships 

Q:  In today’s evolving pharma marketing landscape, how should marketers think about agency structure—particularly when weighing independence versus scale—and what impact does that choice have on partnership, performance, and innovation? 

A:  If I were advising a pharma marketer evaluating agencies today, I’d tell them to prioritize relationships and agility over sheer size. There’s always going to be procurement teams that lean toward the big holding companies because it feels “safer” on paper — but the marketers, the people actually running the brands day to day, want partners they can trust. They want consistency in the team, direct access to decision-makers, and an agency that’s invested in their business, not just their budget. 

When you go with a massive network-affiliated shop, especially in a period of consolidation like we’re seeing right now, there’s a real risk that your account gets lost in the shuffle. Mergers bring layoffs, restructuring, cost pressures — and the service you signed up for might not be what you get a year later. Independents don’t deal with that kind of overhead or bureaucracy. What we do offer is a relationship-driven model where our clients know who’s working on their business and can pick up the phone and get a real decision made quickly. 

At the end of the day, pharma marketing is still a business built on trust and understanding. You want an agency partner who knows your business, understands the regulatory landscape, and can move fast when you need them to. That’s something independents do exceptionally well. So my advice? Don’t get distracted by scale — prioritize partnership. 

The structure and ownership of an agency make a huge difference in how we serve clients and how nimble we can be, especially in pharma where the environment changes fast and you need to be ready to pivot. Having been on both the client and agency side, I can tell you firsthand — independents and holding companies approach things very differently. 

In a holding company model, you’ve got layers of leadership, financial targets from corporate, and sometimes competing priorities across sister agencies. When a big merger happens, like the one we’re seeing now with Omnicom and IPG, cost-cutting and internal politics inevitably affect client service. Teams get leaner, decisions take longer, and it gets harder to deliver truly customized, strategic thinking because there’s so much operational noise. 

On the independent side, we’re not beholden to shareholders or a corporate board. That frees us to be more agile, to make decisions based on what’s right for the client, not what’s going to boost our stock price. It also means clients get to work directly with senior people who stay on their business, not just pitch it. We build real relationships that lead to smarter, faster solutions. 

When we need to try a new approach or shift strategy, we can do it without going through three layers of approval. That ability to be responsive, especially in a highly regulated space like pharma, is invaluable. Our structure keeps us closer to the work and closer to our clients — and that makes us better partners. 

This is one of the most misunderstood dynamics in our business. People assume big holding company agencies have the edge on innovation because they have size, resources, and technology budgets. But in reality, innovation in pharma advertising isn’t about who has the biggest toolbox — it’s about how quickly and confidently you can act within regulatory constraints. And that’s where independent agencies like ours often outperform. 

The truth is, you can’t scale creativity the way you scale media buys. It doesn’t work like that. The best ideas come from tight, collaborative teams who are immersed in the client’s business and empowered to take smart risks. In a holding company environment, even a brilliant idea can get stuck in the gears of corporate processes, legal reviews, and internal politics. By the time it’s approved, it might no longer be relevant. 

At an independent agency, we can vet ideas quickly, course-correct in real time, and push boundaries within what’s legally and ethically sound for our clients. We also embrace technology just as aggressively as the big networks — and, frankly, AI and data tools are becoming more democratized by the day. The notion that holding companies have some insurmountable tech advantage just doesn’t hold up anymore. 

What clients need are partners who are bold but smart — who know how to navigate risk while seizing opportunity. That’s baked into the DNA of independents because we can’t afford to play it safe or get bogged down in bureaucracy. Every piece of business matters, and that urgency fuels better, braver work. 

The biggest misconception I hear is that independent agencies can’t match the resources or capabilities of the big holding company shops — whether it’s in media, technology, or innovation. I get where it comes from. Holding companies have these impressive, massive infrastructures and global reach. But the reality is, especially today, technology levels the playing field. 

For example, one of the reasons holding companies consolidate is to gain efficiencies with things like AI and data platforms. But what happens with technology is that it democratizes. What was once proprietary and premium eventually becomes accessible to everyone. I joke that the supercomputer that filled a room 40 years ago now lives in our phones. The same will happen with AI and martech. 

We’ve already seen it — our agency launched AT Activate last year to strengthen our media offering and it’s performing beyond expectations. We didn’t need to be a holding company to do it. We needed a clear strategy, great leadership, and the freedom to move fast, all things independent agencies have in spades. 

Clients often assume only a network agency can provide scale or cutting-edge solutions, but when you’re working in pharma — where every brand has unique regulatory needs and market dynamics — what matters more is expertise, focus, and partnership. And independents deliver on that every day. So the idea that we’re somehow a step behind in capability just isn’t true anymore. If anything, our flexibility lets us stay ahead. 

AT Perspectives is a forum for AbelsonTaylor Group subject matter experts to weigh in on industry topics. Submit your questions to press@abelsontaylorgroup.com.